Protective Effects of Rifampicin and Its Analog Rifampicin Quinone in a Mouse Model of Obesity-Induced Type 2 Diabetes
Authors:
- Amit GargAGAmit Garg
- Maroof AlamMAMaroof Alam
- Shakuntala BaiSBShakuntala Bai
- Monica DandawateMDMonica Dandawate
- Neeta KumariNKNeeta Kumari
- Sonu GuptaSGSonu Gupta
- Usha AgrawalUAUsha Agrawal
- Perumal NagarajanPNPerumal Nagarajan
- Dumbala Srinivasa ReddyDRDumbala Srinivasa Reddy
- Mahesh J. KulkarniMKMahesh J. Kulkarni
- Arnab MukhopadhyayAMArnab Mukhopadhyay
- 12 January 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 6 (2) , 253-269
Abstract
Advanced glycation end-products (AGEs) form when glucose reacts non-enzymatically with proteins, leading to abnormal protein function, oxidative stress, and inflammation. AGEs are associated with aging and age-related diseases; their formation is aggravated during diabetes. Therefore, drugs preventing AGE formation can potentially treat diabetic complications, positively affecting health. Earlier, we demonstrated that rifampicin and its analogs have potent anti-glycating activities and increase the life span of Caenorhabditis elegans. This study aimed to investigate the effects of rifampicin during hyperglycemia in C. elegans and in a mouse model of obesity-induced type 2 diabetes. The effects of rifampicin were assessed by determining the life span of C. elegans cultured in the presence of glucose and by measuring HbA1c, AGE levels, and glucose excursions in the diabetic mouse model. Our results show that rifampicin protects C. elegans from glucose-induced toxicity and increases life span. In mice, rifampicin reduces HbA1c and AGEs, improves insulin sensitivity, and reduces indications of diabetic nephropathy without inducing hepatotoxicity. Rifampicin quinone, an analog with lower anti-microbial activity, also reduces HbA1c levels, improves glucose homeostasis and insulin sensitivity, and lowers indications of diabetic nephropathy, without adversely affecting the liver of the diabetic mice. Altogether, our results indicate that rifampicin and its analog have protective roles during diabetes without inflicting hepatic damage and may potentially be considered for repositioning to treat hyperglycemia-related complications in patients.Keywords
Funding Information
- Anusandhan National Research Foundation (CRG/2018/003150, PDF/2016/002870, STR/2019/000064)
- Department of Biotechnology , Ministry of Science and Technology (BT/HRD/NBA/38/04/2016, BT/PR23544/MED/30/1858/2017, DBT/JRF/14/AL/242)
This publication has 71 references indexed in Scilit:
- Body mass index, triglycerides, glucose, and blood pressure as predictors of type 2 diabetes in a middle-aged Norwegian cohort of men and womenClinical Epidemiology, 2012
- Rifampicin and Parkinson’s diseaseNeurological Sciences, 2012
- Renal Podocyte Injury in a Rat Model of Type 2 Diabetes Is Prevented by MetforminExperimental Diabetes Research, 2012
- Lactic Acidosis Induced by MetforminDrug Safety, 2010
- C. elegans as Model for the Study of High Glucose– Mediated Life Span ReductionDiabetes, 2009
- New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical DevelopmentAntimicrobial Agents and Chemotherapy, 2009
- RU486 did not exacerbate cytokine release in mice challenged with LPS nor in db/db miceBMC Pharmacology, 2008
- Abdominal obesity and metabolic syndromeNature, 2006
- Administration of AGEs in vivo induces extracellular matrix gene expressionNephrology Dialysis Transplantation, 1996
- The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamideTubercle, 1977